21 Jan, 2022 18-Month Results from HELIOS-A Phase 3 Study of Vutrisiran Presented at SFNP
Positive 18-month results from the HELIOS-A Phase 3 study evaluating vutrisiran, an investigational RNAi therapeutic, in hereditary transthyretin-mediated (hATTR) amyloidosis patients with polyneuropathy, were presented in an oral session at the Société Francophone du Nerf Périphérique (SFNP) Annual Meeting, held January 21-22, 2022.
Adams et al. – “HELIOS-A: Study of Vutrisiran in Patients with hATTR Amyloidosis”
Vutrisiran met all 18-month secondary endpoints, including statistically significant improvements in neuropathy impairment, quality of life (QoL), gait speed, nutritional status and overall disability, relative to external placebo.
Vutrisiran continued to demonstrate halting or reversal of polyneuropathy, with improvements in neuropathy impairment and QoL relative to baseline.
Vutrisiran continued to demonstrate an encouraging safety and tolerability profile.
